Secondary pneumothorax as a potential marker of apatinib efficacy in osteosarcoma: a multicenter analysis
| Autor: | Po Li, Zhichao Tian, Jiaqiang Wang, Weitao Yao, Huimin Liu, Yao Zhao, Hongyan Ren, Peng Zhang, Fan Zhang, Xiaofeng Wang |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Adult
Male 0301 basic medicine Cancer Research medicine.medical_specialty pneumothorax Pyridines Antineoplastic Agents Bone Neoplasms Gastroenterology Clinical Reports Young Adult 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine cavitation Statistical significance Internal medicine tyrosine kinase inhibitors Humans Medicine Pharmacology (medical) In patient Apatinib Retrospective Studies Pharmacology Osteosarcoma Lung business.industry Medical record Prognosis medicine.disease staphylococcal enterotoxin C Survival Rate 030104 developmental biology medicine.anatomical_structure Oncology Pneumothorax chemistry 030220 oncology & carcinogenesis Female business Perfusion apatinib Follow-Up Studies |
| Zdroj: | Anti-Cancer Drugs |
| ISSN: | 0959-4973 |
| DOI: | 10.1097/cad.0000000000001016 |
| Popis: | This study was performed to investigate pneumothorax characteristics and association with clinical outcomes in patients with osteosarcoma treated with apatinib. We retrospectively reviewed the medical records of osteosarcoma patients treated with apatinib between January 2016 and April 2020 at three institutions. We evaluated the prevalence, healing time, recurrence, severity, clinical management, and prognosis of pneumothorax in these patients. A total of 54 osteosarcoma patients who received apatinib treatment were enrolled in this study. Among them, 14 patients had pneumothorax. There were significant differences between the patients with and without pneumothorax with regard to the cavitating rate of lung metastases (92.86 vs. 32.50%, respectively, P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|